Publications dans lesquelles il/elle collabore avec JOSÉ ANTONIO LORENTE ACOSTA (44)

2023

  1. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer

    Biomarker Research

2022

  1. A Novel, Quick, and Reliable Smartphone-Based Method for Serum PSA Quantification: Original Design of a Portable Microfluidic Immunosensor-Based System

    Cancers, Vol. 14, Núm. 18

  2. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

    Theranostics, Vol. 12, Núm. 5, pp. 2150-2161

  3. Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception

    Frontiers in Molecular Biosciences, Vol. 9

  4. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective

    Molecular Genetics and Genomics, Vol. 297, Núm. 3, pp. 859-871

2021

  1. Cross‐resistance to abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by ar transcriptional reactivation

    Cancers, Vol. 13, Núm. 6, pp. 1-21

  2. Deep phenotypic characterisation of CTCs by combination of microfluidic isolation (Isoflux) and imaging flow cytometry (imagestream)

    Cancers, Vol. 13, Núm. 24

  3. Sandwich-Type Electrochemical Paper-Based Immunosensor for Claudin 7 and CD81 Dual Determination on Extracellular Vesicles from Breast Cancer Patients

    Analytical Chemistry, Vol. 93, Núm. 2, pp. 1143-1153

2020

  1. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Critical Reviews in Oncology/Hematology, Vol. 151

  2. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

    Critical Reviews in Oncology/Hematology

  3. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients

    Scientific Reports, Vol. 10, Núm. 1

  4. From precision medicine to imprecision medicine through limited diagnostic ability to detect low allelic frequency mutations

    Translational Lung Cancer Research, Vol. 9, Núm. 2, pp. 180-183

  5. Precision prevention and cancer interception: The new challenges of liquid biopsy

    Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644

  6. Strategies for isolation and phenotypic, genetic, and functional characterization of circulating tumor cells

    Cancers

  7. The polemic diagnostic role of TP53 mutations in liquid biopsies from breast, colon and lung cancers

    Cancers, Vol. 12, Núm. 11, pp. 1-17

2019

  1. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents

    Cells, Vol. 8, Núm. 11

  2. EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform

    Talanta, Vol. 194, pp. 243-252

  3. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

    Breast Cancer Research, Vol. 21, Núm. 1

  4. Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity

    Critical Reviews in Oncology/Hematology, Vol. 136, pp. 31-36

  5. Post-surgery circulating tumor cells and AXL overexpression as new poor prognostic biomarkers in resected lung adenocarcinoma

    Cancers, Vol. 11, Núm. 11